Dementia in Parkinson's disease

Current Treatment Options in Neurology

Volumn 6, Issue 3, 2004, Pages 201-207

  Anderson, Karen E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; GINKGO BILOBA EXTRACT; LIVER ENZYME; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLSERINE; PIRACETAM; RIVASTIGMINE; SELEGILINE; TACRINE; TOCOPHEROL; UBIDECARENONE;

AGING; ALZHEIMER DISEASE; AMNESIA; ANOREXIA; ATTITUDE; BODY WEIGHT DISORDER; BRAIN DEPTH STIMULATION; CARDIOVASCULAR DISEASE; CAREGIVER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DELUSION; DEMENTIA; DEPRESSION; DEVICE; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DISTRESS SYNDROME; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXERCISE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLOBUS PALLIDUS; HALLUCINATION; HERBAL MEDICINE; HUMAN; LIFESTYLE; LIVER TOXICITY; MENTAL DISEASE; MOBILIZATION; MORBIDITY; MOTOR PERFORMANCE; MUSCLE CRAMP; NAUSEA; NEUROPATHOLOGY; NEUROPROTECTION; PARKINSON DISEASE; PATIENT CARE; PEPTIC ULCER; PHYSIOTHERAPY; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; SLEEP DISORDER; SUBTHALAMIC NUCLEUS; TOBACCO; TREMOR; VOMITING; WELLBEING;

EID: 3142749064     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-004-0012-9     Document Type: Review

References (24)

1. Cummings JL: Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988, 1:24-36.
2. Aarsland D, Andersen K, Larsen JP, et al.: Risk of dementia in Parkinson's disease: a community based prospective study. Neurology 2001, 56:730-736.
3. Hindle JV: Dementia in PD. In Parkinson's Disease in the Older Patient. Edited by Payfer JR, Hindle JV. London: Arnold Press; 2001:3-117.
4. Green J, McDonald WM, Vitek JL, et al.: Cognitive impairments in advanced PD without dementia. Neurology 2002, 59:1320-1324.
5. Levy G, Schupf N, Tang M-X, et al.: Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002, 51:722-729.
6. Levy G: Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 2002, 17:250-257.
7. Colosimo C, Hughes AJ, Kilford L, Less AJ: Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003, 74:852-856.
8. Murat E: What causes mental dysfunction in Parkinson's Disease? Mov Disord 2003, 18(suppl):S63-S71.
9. Tiraboschi P, Hansen LA, Alford M, et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407-411.
10. McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000, 356:2031-2036.
11. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996, 61:324-326.
12. Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002, 72:708-712.
13. Werber EA, Rabey Jm: The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001, 108:1319-1325.
14. Kurita A, Ochiai Y, Kono Y, et al.: The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003, 16:184-186.
15. Fabbrini G, Barbanti P, Aurilia C, et al.: Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002, 23:41-43.
16. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001, 16:1171-1174.
17. Bullock R, Cameron A: Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002, 18:258-264.
18. Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003, 18:937-941.
19. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R: Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999, 22:273-276.
20. Sano M, Stern Y, Marder K, et al.: A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease. Mov Disord 1990, 5:230-234.
21. Furigeld E, Gaggen M, Nedwick P, et al.: Double-blind study with phosphatidylserine in parkinsonian patients with senile dementia of the Alzheimer's type (SDAT). Prog Clin Biol Res 1989, 317:1235-1246.
22. Keiburtz K: The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson's Study Group. Neurology 1994, 44:1756-1759.
23. Shoulson I: Where do we stand on neuroprotection? Where do we go from here? Mov disord 1998, 13(suppl):46-48.
24. Kieburtz K: Designing neuroprotection trials in Parkinson's disease. Ann Neurol 2003, 53(suppl):S100-S107.